Cadrenal Therape SEC Filings

Cadrenal Therapeutics insider sale disclosure: Quang Pham, who serves as CEO and Chairman and is a director and 10% owner, reported open-market sales of the companys common stock on August 27 and August 28, 2025. On August 27 Mr. Pham sold 3,836 shares at a weighted average price of $13.99, reducing his reported direct beneficial ownership to 214,497 shares. On August 28 he sold 1,193 shares at a weighted average price of $13.99, reducing direct beneficial ownership to 213,304 shares. He also reports indirect ownership of 200,000 shares held by The PVBQ Living Trust, for which he is trustee. The filing indicates the transactions were made pursuant to a written plan consistent with Rule 10b5-1 and is signed by an attorney-in-fact on August 29, 2025.

Form 144 notice for proposed sale of securities under Rule 144. The filing shows an intended sale of 1,193 common shares through Merrill Lynch on 08/28/2025 with an aggregate market value of $16,540.64. The shares were acquired as founders shares on 01/25/2022 from the company. The filing reports 2,046,854 shares outstanding for the class listed. Separately, the document discloses a recent sale by Quang Pham of 3,836 common shares on 08/27/2025 that generated $53,455.56 in gross proceeds. The issuer name and CIK are not provided in the visible content, and the filer contact details are blank.

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 declaring a proposed sale of 400 founder shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $5,572.00. The filing lists 2,046,854 shares outstanding and an approximate sale date of 08/28/2025 on NASDAQ. The shares were acquired as founders shares on 05/17/2022 from the issuer and payment was recorded on the same date. The filing also discloses recent 10b5-1 sales by the same person: 1,600 shares sold on 08/27/2025 for gross proceeds of $22,392.00. The filer affirms compliance statements required under Rule 144 and 10b5-1.

Cadrenal Therapeutics (CVKD) filed a Form 144 to notify a proposed sale of 1,600 common shares$22,000. The filing shows 2,046,854 shares outstanding, so the notice covers a very small portion of the company’s outstanding stock. The shares were acquired as founders shares on 05/17/2022 and no payment financing arrangements are indicated. The planned approximate sale date is 08/27/2025. The filer reports no securities sold in the prior three months.

Cadrenal Therapeutics, Inc. (CVKD) filed an amended Form 144 disclosing a proposed sale of 3,836 common shares through Merrill Lynch on the NASQ exchange with an approximate aggregate market value of $53,455.56 and 2,046,854 shares outstanding. The shares were acquired on 01/25/2022 in a private placement from the company and were paid in full on that date. The filing reports no securities sold in the past three months for the account and includes the seller's representation that they are not aware of undisclosed material adverse information regarding the issuer.

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying a proposed sale of 30,600 common shares held by the filer. The shares were acquired in a private placement on 01/25/2022 and the aggregate market value of the shares to be sold is listed as $428,094.00. The form identifies Merrill Lynch (Ponte Vedra Beach, FL) as the broker and lists an approximate sale date of 08/27/2025 on the NASQ exchange. The filing states no securities were sold by the filer in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

On August 11, 2025, Cadrenal Therapeutics, Inc. filed a Form 8-K reporting that it issued a press release containing financial information for the fiscal quarter ended June 30, 2025, furnished as Exhibit 99.1 to the report. The filing identifies the company as an emerging growth company and shows its common stock is listed on the Nasdaq Capital Market under the symbol CVKD. The filing also furnishes the cover page interactive XBRL as Exhibit 104 and was signed by Quang X. Pham, Chairman and Chief Executive Officer.

The company states the press release and Item 2.02 disclosure are furnished, not "filed" for purposes of Section 18, and will not be incorporated by reference into other SEC filings.

Cadrenal Therapeutics (CVKD) reported unaudited results for the quarter ended June 30, 2025 showing a quarterly net loss of $3.67 million and a six‑month net loss of $7.51 million. Cash and cash equivalents were $5.57 million at June 30, 2025 and approximately $5.0 million as of August 6, 2025, which the company states is expected to fund operations for at least the next twelve months from the filing date. Working capital was about $4.3 million and the accumulated deficit stood at $33.2 million. As of August 11, 2025, there were 2,046,854 shares outstanding.

Operating expenses increased year‑over‑year: six‑month general and administrative expenses rose to $4.91 million (110% increase) and research and development expenses rose to $2.75 million (46% increase) driven by CMC, personnel and clinical preparation costs. Financing activity included $3.35 million gross ATM proceeds in H1 2025 and an additional ~$516,000 gross via ATM in July 2025. Tecarfarin holds orphan and fast‑track designations for specified indications and the company announced clinical trial initiation plans for ESKD patients transitioning to dialysis on August 5, 2025.